Gail Farfel

(Dr. Gail Farfel Ph.D.)

Currently holds positions in Zogenix Inc and DURECT Corp

Positions
Position Company Period
Executive Vice President, Chief Development Officer Zogenix Inc July 6, 2015 -
Independent Director DURECT Corp April 23, 2019 -
Chief Clinical Development and Regulatory Officer Marinus Pharmaceuticals Inc Dec. 1, 2012 - Jan. 1, 2015
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Total value Details
2022-12-16 2022-12-14
B Purchase
1,000 +100.0%
4.94
4,940 USD 		1,000 +100.0% 4.94 4,940 USD
2022-12-08 2022-12-06
B Purchase
1,000 +inf%
5.70
5,700 USD 		1,000 +inf% 5.70 5,700 USD
2022-05-18 2022-05-18
US DURECT Corp (DRRX)
B Purchase
29,911 +42.7%
0.41
12,201 USD 		29,911 +42.7% 0.41 12,201 USD
2022-05-18 2022-05-16
US DURECT Corp (DRRX)
B Purchase
25,300 +56.5%
0.39
9,811 USD 		25,300 +56.5% 0.39 9,811 USD
2022-05-13 2022-05-13
US DURECT Corp (DRRX)
B Purchase
9,250 +26.0%
0.40
3,700 USD 		9,250 +26.0% 0.40 3,700 USD
2022-05-13 2022-05-12
US DURECT Corp (DRRX)
B Purchase
1,500 +4.4%
0.39
585 USD 		1,500 +4.4% 0.39 585 USD
2022-05-13 2022-05-11
US DURECT Corp (DRRX)
B Purchase
9,950 +41.3%
0.40
3,973 USD 		9,950 +41.3% 0.40 3,973 USD
2022-05-12 2022-05-10
US DURECT Corp (DRRX)
B Purchase
2,339 +10.8%
0.41
950 USD 		2,339 +10.8% 0.41 950 USD
2022-05-10 2022-05-10
US DURECT Corp (DRRX)
B Purchase
4,250 +24.3%
0.40
1,679 USD 		4,250 +24.3% 0.40 1,679 USD
2022-05-10 2022-05-09
US DURECT Corp (DRRX)
B Purchase
17,500 +inf%
0.39
6,906 USD 		17,500 +inf% 0.39 6,906 USD
2020-05-13 2020-05-12
US Zogenix Inc (ZGNX)
PS Planned sale
2,573 -33.8%
28.21
72,584 USD 		2,573 -33.8% 28.21 72,584 USD
2015-04-23 2015-04-21
PS Planned sale
30,000 -100.0%
9.48
284,511 USD 		30,000 -100.0% 9.48 284,511 USD